Semuloparin sodium
As of the edition of 20 October 2026, Semuloparin sodium is an oligosaccharide: stopped in 2012; acts on SERPINC1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2012
- Kind
- Oligosaccharide
- Registered trials
- 9, 2 stopped early
- Disease areas
- Heart and blood vessels; Cancer; Injuries
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| SERPINC1 | Antithrombin-III | P01008 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 2 | 1 | 0 | 1 |
| Phase 3 | 7 | 6 | 0 | 1 |
| All trials | 9 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Sanofi | Lead sponsor of trials | 2006 to now |